List of Excipients in Branded Drug ACANYA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	ACANYA	clindamycin phosphate and benzoyl peroxide	13548-132	CARBOMER HOMOPOLYMER TYPE C
Bausch Health US LLC	ACANYA	clindamycin phosphate and benzoyl peroxide	13548-132	POTASSIUM HYDROXIDE
Bausch Health US LLC	ACANYA	clindamycin phosphate and benzoyl peroxide	13548-132	PROPYLENE GLYCOL
Bausch Health US LLC	ACANYA	clindamycin phosphate and benzoyl peroxide	13548-132	WATER

ACANYA Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

Acanya is a prescription topical acne gel containing clindamycin phosphate 1.2% and benzoyl peroxide 2.5%. Its commercial value depends less on the active ingredients, which are mature and widely available, than on formulation stability, skin tolerability, packaging, preservative control, and regulatory positioning. The strongest opportunities are differentiated generic products, improved aqueous gels, airless packaging, lower-irritation formulations, and fixed-dose combinations that preserve antibiotic stewardship requirements.

What is Acanya and how does its formulation work?

Acanya combines a topical antibiotic with an oxidizing antimicrobial:

Attribute	Acanya
Active ingredients	Clindamycin phosphate 1.2%; benzoyl peroxide 2.5%
Dosage form	Topical gel
Therapeutic area	Acne vulgaris
Regulatory category	Prescription drug
Pharmacologic roles	Antibacterial, anti-inflammatory, comedolytic
Primary formulation challenge	Maintaining clindamycin stability in the presence of benzoyl peroxide
Primary commercial challenge	Competing against generic clindamycin/benzoyl peroxide products and low-cost separate therapies

The fixed-dose combination addresses two different acne mechanisms. Benzoyl peroxide reduces Cutibacterium acnes and helps limit antibiotic resistance. Clindamycin provides antibacterial and anti-inflammatory activity. The formulation must deliver both components uniformly without excessive irritation, phase separation, loss of viscosity, or degradation during storage.

Acanya was developed as an aqueous gel rather than as an anhydrous benzoyl peroxide system. That choice supports spreadability and patient acceptability but increases the importance of pH control, polymer selection, preservative strategy, and packaging.

What excipients are used in Acanya?

Public product labeling identifies the principal inactive ingredients as carbomer 934P, glycerin, potassium hydroxide, and purified water.[1] The excipient system has four functional roles:

Excipient or class	Formulation role	Commercial relevance
Carbomer 934P	Gelling agent and rheology modifier	Controls viscosity, suspension, spreadability, and residence time
Glycerin	Humectant and solvent-support component	Reduces drying and improves skin feel
Potassium hydroxide	Neutralizer and pH adjuster	Activates carbomer viscosity and controls chemical stability
Purified water	Continuous phase	Supports the aqueous gel structure and ingredient delivery

The listed excipients are conventional, low-cost materials. Their strategic importance comes from interaction effects rather than individual novelty.

Carbomer selection

Carbomer 934P provides a crosslinked acrylic polymer network that thickens after neutralization. It can suspend benzoyl peroxide particles and produce a gel that remains on the skin long enough for drug delivery.

A reformulator could evaluate:

• Carbomer 980 or 974P for altered yield stress and suspension performance.
• Acrylates/C10-30 alkyl acrylate crosspolymer for improved electrolyte tolerance.
• Hydroxyethylcellulose or xanthan gum where a softer, less tacky texture is preferred.
• Polymer blends to reduce stringiness and improve pump dispensing.
• Lower-viscosity systems for better facial spread and reduced residue.

The main risk is that polymer substitution changes the product's microstructure, rheology, drug release, and potentially its regulatory pathway. A generic sponsor must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA framework, while a reformulated product may require a new drug application or a more extensive bridge.

Glycerin and skin tolerability

Glycerin offsets the drying effect associated with benzoyl peroxide. It also improves glide and reduces the perception of tightness after application. Excessive glycerin, however, can increase tackiness and interfere with consumer acceptance.

Commercially useful optimization targets include:

• Lower tack without reducing moisturization.
• Compatibility with sensitive-skin positioning.
• Reduced flaking during the first weeks of treatment.
• Improved compatibility with facial moisturizers and sunscreen.
• Better feel under cosmetics.

A formulation with superior tolerability can support higher adherence and potentially justify a premium over commodity generic gels.

Potassium hydroxide and pH control

Potassium hydroxide neutralizes carbomer and establishes the pH required for gel structure. Its concentration must be controlled tightly because small pH changes can affect:

• Carbomer viscosity.
• Clindamycin phosphate stability.
• Benzoyl peroxide decomposition.
• Skin irritation.
• Preservative performance.
• Drug release from the gel matrix.

The optimal pH is a formulation trade-off. Higher pH can improve carbomer thickening but may increase irritation or alter active stability. Lower pH can weaken the gel and change drug release. The target should be established through stability, rheology, release, and skin-compatibility studies rather than by excipient convention.

What excipient strategy is most attractive for an Acanya successor?

The most defensible strategy is a stability-first aqueous gel with controlled rheology, low-irritation excipients, and packaging that limits oxygen, light, and contamination.

Strategy 1: Preserve the established aqueous gel platform

This is the lowest-risk approach for a generic or authorized-generic product. The sponsor retains:

• Clindamycin phosphate 1.2%.
• Benzoyl peroxide 2.5%.
• Carbomer-based aqueous gel.
• Glycerin-containing moisturization.
• Potassium hydroxide pH adjustment.

The commercial advantage is a familiar dosage form with a lower development burden. The disadvantage is limited differentiation and high price pressure.

Strategy 2: Develop a low-irritation gel

A differentiated product could use a modified humectant system, polymer blend, or emollient-compatible aqueous gel to reduce dryness and burning. Potential excipient directions include:

• Glycerin combined with propanediol or other humectants.
• Small quantities of skin-conditioning agents compatible with benzoyl peroxide.
• Lower-residue carbomer systems.
• Poloxamer or cellulose-polymer support for improved slip.
• Reduced surfactant content to limit irritation.

The formulation must avoid ingredients that accelerate benzoyl peroxide decomposition or create unacceptable preservative interactions.

Strategy 3: Use an airless or metered-dose delivery system

Packaging is one of the clearest opportunities for product differentiation. An airless pump can reduce:

• Exposure to oxygen.
• Repeated jar contamination.
• Dose variability.
• Product oxidation.
• Consumer contact with the formulation.

A metered pump can improve adherence by delivering a reproducible quantity. The sponsor would need to validate pump compatibility, extractables and leachables, priming, dose uniformity, residual product, and container-closure integrity.

The packaging itself may be protectable through device or combination-product claims, even where the underlying active ingredient combination is no longer strongly protected.

Strategy 4: Improve benzoyl peroxide particle control

Benzoyl peroxide can be present as suspended particles in an aqueous gel. Particle size affects:

• Grittiness.
• Sedimentation.
• Skin feel.
• Dissolution and release.
• Irritation.
• Physical stability.

A narrower particle-size distribution and improved wetting system could produce a smoother product. The sponsor should avoid aggressive surfactant systems that increase irritation or destabilize the active.

Strategy 5: Develop a preservative-minimized system

Aqueous topical products face microbial-control requirements. A preservative-minimized or preservative-free presentation could provide a commercial advantage for sensitive-skin users, but it requires a robust microbial-control strategy.

Potential approaches include:

• Airless packaging.
• Single-use or unit-dose packaging.
• Low-water or water-reduced gels.
• Preservative systems with strong skin tolerability.
• Validated antimicrobial packaging components.

A preservative-free claim is commercially attractive but can increase manufacturing complexity, packaging cost, and regulatory testing requirements.

What formulation patents could protect an Acanya successor?

Formulation patent value would likely come from technical performance rather than the basic active combination. The strongest claim categories are:

Stability patents

Potential claims could cover:

• Stabilized clindamycin and benzoyl peroxide combinations.
• Defined pH ranges.
• Specific polymer-neutralizer ratios.
• Reduced benzoyl peroxide degradation.
• Defined impurity limits after accelerated storage.
• Oxygen-limiting packaging.

Rheology and particle-size patents

Claims could focus on:

• Specific carbomer or polymer combinations.
• Benzoyl peroxide particle-size distributions.
• Yield stress and viscosity ranges.
• Suspension stability.
• Reduced grittiness.
• Controlled drug release.

Tolerability patents

Potential claim themes include:

• Reduced irritation compared with reference formulations.
• Specified humectant combinations.
• Lower drying or erythema scores.
• Compatibility with sensitive skin.
• Reduced bleaching or residue.

Delivery-system patents

Potential claims could cover:

• Metered-dose pumps.
• Airless containers.
• Dual-chamber systems.
• Unit-dose packs.
• Container-closure systems that reduce benzoyl peroxide degradation.

The commercial strength of such patents depends on whether the claims require a technically meaningful composition or merely recite conventional excipients at broad concentrations. Narrow, data-supported claims are more likely to withstand validity challenges than broad claims directed to routine carbomer, glycerin, water, and pH-adjustment combinations.

When does Acanya lose exclusivity and what is the generic-entry risk?

Acanya's active ingredients are long-established. The principal market barriers are therefore likely to be product-specific formulation rights, regulatory exclusivity, manufacturing know-how, and market access rather than basic composition-of-matter protection.

FDA regulatory exclusivity for a conventional topical combination is generally limited compared with the commercial life of the product. The main generic pathway is an abbreviated new drug application where a sponsor can establish equivalence to the reference product. The relevant risks include:

Risk area	Impact on Acanya competition
Paragraph IV certification	Can trigger patent litigation and a 30-month stay if applicable patent listings are challenged
Formulation equivalence	May create development risk if the reference product has complex microstructure
Topical bioequivalence	May require comparative dermatopharmacokinetic, in vitro release, or clinical evidence
Manufacturing scale-up	Can change particle suspension, viscosity, and dose delivery
Packaging	May affect stability and container-closure performance
Market withdrawal	Can complicate reference-product sourcing and regulatory strategy

A generic entrant could pursue a direct equivalent, a product with a different but acceptable inactive-ingredient profile, or a separate clindamycin and benzoyl peroxide regimen. The first approach has the lowest commercial differentiation but the clearest substitution case.

What is the Orange Book and FDA regulatory status of Acanya?

The Orange Book is the controlling FDA reference for approved drug products, therapeutic-equivalence evaluations, patent listings, and regulatory exclusivity.[2] Acanya's regulatory position should be assessed through its FDA approval record and current marketing status.

For commercial planning, the relevant FDA questions are:

1. Is Acanya listed as the current reference listed drug?
2. Is the product listed as discontinued because of commercial reasons or because FDA withdrew approval for safety or effectiveness?
3. Are patents still listed for the reference product?
4. Is a therapeutically equivalent generic approved?
5. Does the proposed product qualify for an ANDA pathway?
6. Are there FDA-approved alternatives with the same active ingredients and strengths?

The distinction between "discontinued marketing" and "withdrawn approval" matters. A discontinued product can remain the reference product for generic development. A withdrawn approval can materially change the filing strategy.

Which companies compete with Acanya?

Competition comes from three groups:

Fixed-dose clindamycin and benzoyl peroxide products

These products compete most directly with Acanya. Examples include Benzaclin and generic clindamycin phosphate/benzoyl peroxide products. Differences can include benzoyl peroxide strength, gel vehicle, packaging, storage requirements, and price.

Separate active therapies

Dermatologists may prescribe:

• Benzoyl peroxide alone.
• Clindamycin with separate benzoyl peroxide.
• Adapalene and benzoyl peroxide.
• Tretinoin-based combinations.
• Topical minocycline.
• Azelaic acid.
• Oral antibiotics for more severe disease.

Separate therapy can reduce dependence on a single fixed-dose product but may lower adherence.

Newer branded acne products

Newer products compete through:

• Improved tolerability.
• Novel topical antibiotics.
• Retinoid combinations.
• Foam or cream vehicles.
• Lower-irritation delivery systems.
• Cosmetic elegance.

Acanya's best commercial position is a well-tolerated, lower-cost combination with convenient dosing and reliable packaging.

How does Acanya compare with competing acne combinations?

Product type	Main advantage	Main weakness	Excipient opportunity
Acanya-type clindamycin/BPO gel	Established dual mechanism	Generic pricing and irritation	Better feel, stability, packaging
Benzaclin-type clindamycin/BPO gel	Direct clinical substitute	Similar antibiotic and irritation concerns	Improved preservative and pump system
Adapalene/BPO	Retinoid plus antimicrobial activity	Retinoid irritation	Barrier-supportive vehicle
Separate clindamycin plus BPO	Flexible dosing	More steps and poorer adherence	Fixed-dose convenience
BPO monotherapy	Low cost and resistance benefit	Less anti-inflammatory activity	Cosmetic elegance and reduced dryness
Newer topical antibiotic products	Potentially improved tolerability	Higher cost and limited access	Premium delivery platform

The key differentiator is not simply the active-ingredient combination. It is whether the product improves adherence without undermining stability or increasing development costs.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are practical rather than exotic. A commercial-scale process must control:

• Benzoyl peroxide dispersion.
• Polymer hydration.
• Neutralization sequence.
• Mixing shear.
• Temperature exposure.
• Air incorporation.
• Fill weight.
• Pump performance.
• Microbial quality.
• Active uniformity.

The order of addition can affect gel structure and particle distribution. High shear can alter polymer viscosity or introduce air. Excessive heat can accelerate benzoyl peroxide decomposition. Scale-up therefore requires process controls that are closely linked to the formulation's critical quality attributes.

Potential trade-secret protection may cover:

• Mixing sequence.
• Shear profile.
• Raw-material specifications.
• Particle wetting.
• Deaeration.
• Filling conditions.
• Stability-indicating analytical methods.

These know-how rights can delay a competitor even where patent protection is weak, but they do not prevent independent development.

What licensing and partnership opportunities exist?

The most realistic licensing opportunities involve formulation platforms, packaging technology, or regional commercialization rather than rights to clindamycin or benzoyl peroxide.

Potential deal structures include:

Opportunity	Likely partner	Value proposition
Airless topical packaging	Device or packaging company	Improved stability and dose consistency
Low-irritation aqueous gel	Dermatology specialty company	Premium differentiation
Generic Acanya equivalent	ANDA developer or manufacturer	Fast market entry
Regional rights	Specialty pharmaceutical company	Local registration and distribution
Dermatology portfolio acquisition	Private-label or branded-generic company	Cross-selling through existing channels
Formulation technology license	Excipients or drug-delivery company	Access to validated polymer and release systems

A licensing transaction would be more attractive if supported by comparative stability data, in vitro release data, dermatology tolerability results, and a clear FDA filing route.

What revenue exposure and launch scenarios exist?

Acanya is exposed to rapid price erosion if several therapeutically equivalent generics enter. A branded reformulation could preserve revenue through differentiated positioning, but the addressable market is constrained by:

• Generic substitution.
• Low-cost BPO alternatives.
• Antibiotic stewardship concerns.
• Dermatology formulary controls.
• Patient sensitivity to copay and deductible costs.

Three launch scenarios are commercially relevant:

Commodity generic launch

The sponsor matches the reference product closely and competes on price. This approach has the lowest differentiation and the greatest exposure to rapid erosion.

Value-added generic launch

The sponsor uses improved packaging, better pump dosing, or a more acceptable vehicle. This supports a moderate premium if the product remains substitutable or is covered by payers.

Branded reformulation

The sponsor pursues a materially differentiated vehicle, lower-irritation profile, or preservative-minimized system. This can support premium pricing but may require a new regulatory strategy and clinical or comparative performance evidence.

How strong is the commercial patent estate for Acanya?

The underlying active ingredients have limited strategic exclusivity value because clindamycin and benzoyl peroxide are mature compounds. The defensible portion of the estate is more likely to involve:

• Specific fixed-dose formulation architecture.
• Stability controls.
• Vehicle composition.
• Packaging.
• Manufacturing methods.
• Clinical or pharmacokinetic performance tied to the formulation.

Patent strength should be judged claim by claim. A patent that requires a narrow pH range, specific polymer grade, defined particle size, and demonstrated stability may have meaningful blocking value. A patent covering broad classes of conventional topical excipients is more vulnerable to invalidity and design-around strategies.

Key takeaways

• Acanya is a clindamycin phosphate 1.2% and benzoyl peroxide 2.5% aqueous gel.
• Its principal labeled excipients are carbomer 934P, glycerin, potassium hydroxide, and purified water.[1]
• The central technical problem is maintaining benzoyl peroxide stability while preserving clindamycin performance, gel viscosity, and skin tolerability.
• The strongest product opportunities are low-irritation vehicles, improved benzoyl peroxide dispersion, airless pumps, metered dosing, and preservative-minimized systems.
• The primary competitive threat is generic fixed-dose clindamycin/benzoyl peroxide, followed by separate active regimens and newer acne combinations.
• Patent value is likely to reside in formulation, packaging, manufacturing, and stability claims rather than the active ingredients.
• FDA Orange Book status, reference-listed-drug status, patent listings, and current marketing status determine the most efficient generic pathway.[2]
• A commodity generic can enter at lower cost, while a differentiated formulation has greater revenue potential but a higher regulatory and development burden.

FAQs

Can Acanya be reformulated with a different carbomer?

Yes. A different carbomer or polymer blend may be used if the product meets applicable pharmaceutical-equivalence, performance, stability, and regulatory requirements. The change can affect viscosity, drug release, particle suspension, and skin feel.

Is benzoyl peroxide compatible with all topical preservatives?

No. Compatibility depends on the preservative chemistry, pH, water activity, packaging, and benzoyl peroxide degradation profile. Each candidate system requires stability and microbial-control testing.

Could an Acanya successor use a foam instead of a gel?

Yes, but a foam would be a new dosage-form strategy rather than a simple vehicle substitution. It would require development of active uniformity, foam performance, propellant or package compatibility, dose delivery, stability, and regulatory comparability.

Does an airless pump create patentable value?

It can. Patentability is stronger when the pump is linked to a technical result such as reduced benzoyl peroxide degradation, improved dose uniformity, or extended in-use stability. A generic pump concept alone may provide limited protection.

Is a clindamycin and benzoyl peroxide product suitable for over-the-counter commercialization?

A fixed-dose product containing prescription clindamycin would generally require a prescription regulatory pathway in the United States. Benzoyl peroxide alone has an established OTC acne framework, but adding clindamycin materially changes the regulatory classification and antibiotic-stewardship analysis.

References

1. U.S. Food and Drug Administration. (n.d.). Acanya (clindamycin phosphate and benzoyl peroxide) gel: Prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.